Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients' lives with best-in-class medicines, today announced the appointment of Lawrence M. Blatt, PhD, MBA as Chair of its Board of Directors. Dr. Blatt brings substantial expertise in strategic leadership, drug development and operations together with extensive experience, […]

Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted Therapeutics in Solid Tumors and Fibrosis Company has built one of the largest proprietary extracellular matrix (ECM) datasets spanning fibrosis and solid tumors GlobeNewswire January 08, 2026 LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Engitix Ltd (“Engitix”), a biotech

Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics GlobeNewswire January 08, 2026 Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients' lives with best-in-class medicines, today announced the appointment of Lawrence M. Blatt, PhD, MBA as Chair of its Board of

PathAI and University Hospital Zurich Announce Collaboration to Deploy AISight(R) Dx and AIM-TumorCellularity for Routine Molecular Pathology Workflows GlobeNewswire January 08, 2026 BOSTON, Mass. and ZURICH, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) — PathAI, a global leader in AI-powered pathology, today announced a strategic collaboration with University Hospital Zurich (USZ) to deploy AISight(R) Dx1, PathAI's

(TSE:4565.T), Vamorolone is approved and marketed as AGAMREE(R) for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and China New five-year data on vamorolone highlighted substantially improved safety profile with reduced vertebral fractures, lower incidence of cataracts and that normal growth rate was maintained. With adverse effects being a key

Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals GlobeNewswire January 08, 2026 Vamorolone is approved and marketed as AGAMREE(R) for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and China New five-year data on vamorolone highlighted substantially improved safety profile with

Hall Chadwick, the leading Australian-founded professional services firm with a 138-year legacy, will host an invitation-only investment forum in Singapore in March 2026, bringing together senior corporate leaders, global capital markets advisers and institutional investors to examine how Asia-Pacific companies can navigate evolving global capital markets and access deeper pools of capital, liquidity and strategic

(SWX:SANN), Ad hoc announcement pursuant to Art. 53 LR Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, a 20% premium to the 30-day VWAP. Pratteln, Switzerland, January 8, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces it has signed

Santhera Licenses AGAMREE(R) (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties GlobeNewswire January 08, 2026 Ad hoc announcement pursuant to Art. 53 LR Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD

(Euronext Amsterdam:SHELL),(LSE:SHEL),(NYSE:SHEL), The following is an update to the fourth quarter 2025 outlook and gives an overview of our current expectations for the fourth quarter. Outlooks presented may vary from the actual fourth quarter 2025 results and are subject to finalisation of those results, which are scheduled to be published on February 5, 2026. Unless